Menu Search
Equities

Beijing Biostar Pharmaceuticals Co Ltd

  • Add to watchlist
  • Add to portfolio
  • Add an alert
2563:HKG.HS

Beijing Biostar Pharmaceuticals Co Ltd

Actions
  • Price (HKD)3.76
  • Today's Change0.07 / 1.90%
  • Shares traded14.20k
  • 1 Year change-75.52%
  • Beta--
Data delayed at least 15 minutes, as of Feb 13 2026 05:42 GMT.
More ▼
Notice
Important Notice
Please note that effective 5th February, 2026 the Financial Times will no longer publish or present securities from the Nairobi Stock Exchange.

Profile data is unavailable for this security.

About the company

Beijing Biostar Pharmaceuticals Co Ltd is a Chinea-based company principally engaged in the research, development, production and sales of innovative drugs. The Company's products and pipeline mainly include Utidelone Injection, Utidelone Capsule, Utidelone Nanoformulation, Utidelone Antibody Drug Conjugate (ADC), BG22, BG18 and BG44. The Company's products are principally used for the treatment of relapsed or metastatic breast cancer, neoadjuvant treatment of human epidermal growth factor receptor 2 (HER2)-breast cancer neoadjuvant, advanced non-small cell lung cancer (NSCLC), solid tumors, breast cancer brain metastasis, lung cancer brain metastasis and other brain tumor indications. The Company mainly conducts its businesses in the domestic market.

  • Revenue in HKD (TTM)--
  • Net income in HKD--
  • Incorporated2002
  • Employees147.00
  • Location
    Beijing Biostar Pharmaceuticals Co Ltd1202, Tower BYicheng Fortune Center,Beijing Economic-BEIJING ChinaCHN
  • Websitehttps://www.biostar-pharm.com/
More ▼
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.